You are here: Industry Insights > Market News > US FDA completes inspection of Lupin’s Pithampur Unit-2 (Indore) facility

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

US FDA completes inspection of Lupin’s Pithampur Unit-2 (Indore) facility

expressbpdFebruary 12, 2019

Tag: lupin , Inspection , FDA

Favorites

US FDA completes inspection of Lupin’s Pithampur Unit-2 (Indore) facility.

US FDA completes inspection of Lupin’s Pithampur Unit-2 (Indore) facility

Lupin announced the completion of the United States Food and Drug Administration (US FDA) inspection carried out at its Pithampur Unit -2 (Indore) facility. The inspection was carried out between January 14 and January 25, 2019.

The inspection at Pithampur Unit-2 (Indore) closed with six observations. The company is confident ofaddressing the observations satisfactorily.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:Aurobindo acquires Apotex’s operations in five European countries

Next:WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress

PharmaSourcesJune 14, 2024

Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

PharmaSourcesJune 11, 2024

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress

PharmaSourcesJune 05, 2024

US FDA completes inspection of Lupin’s Pithampur Unit-2 (Indore) facility | Pharmasources.com

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs

PharmaSourcesJune 05, 2024

New research showes that biotechs can save more than 30% in costs, halve start-up times, and cut risk with CROs that have in-house scientific and regulatory affairs.

US FDA completes inspection of Lupin’s Pithampur Unit-2 (Indore) facility

Related News

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs

You may like